{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:04:29Z","timestamp":1783904669056,"version":"3.55.0"},"reference-count":44,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Flow cytometry plays is important in the diagnosis of acute lymphoblastic leukaemia (ALL) and when antigen-specific immunotherapy is indicated. We have investigated the effects of prednisolone, vincristine, daunorubicin, asparaginase and methotrexate on the antigen expression on blast cells that could influence the planning of antigen-specific therapy as well as risk-based treatment assignment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>\n                      Patients aged \u2264 17 years with\n                      <jats:italic>de novo<\/jats:italic>\n                      B-cell ALL (B-ALL) were enrolled in the study. Blast cells were isolated and exposed\n                      <jats:italic>in vitro<\/jats:italic>\n                      to 5 individual cytotoxic drugs in logarithmically increasing concentrations. Then, the expression of CD10, CD19, CD20, CD27, CD34, CD45, CD58, CD66c and CD137 antigens was determined by quantitative flow cytometry.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Cytotoxic drugs caused dose-dependent or dose-independent modulation of antigen expression. Daunorubicin caused a dose-dependent down-modulation of CD10, CD19, CD34, CD45 and CD58 and an up-modulation of CD137. Vincristine caused a dose-dependent down-modulation of CD19 and CD58 and an up-modulation of CD45. Daunorubicin also caused dose-independent down-modulation of CD27 and prednisolone down-modulation of CD10, CD19, CD27, CD34 and CD58. Down-modulation of CD20 was detected only in relation to the specific dose of daunorubicin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results of the study have shown that cytotoxic drugs can alter the expression of antigens that are important for immunotherapy. Importantly, daunorubicin, prednisolone and vincristine caused down-modulation of CD19 and CD58, suggesting that these drugs are better avoided during bridging therapy prior to bispecific antibodies or CAR-T cell therapy. In addition, immunophenotypic changes on blast cells induced by different drugs could also influence risk-based treatment assignment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/raon-2024-0006","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T18:46:32Z","timestamp":1708454792000},"page":"133-144","source":"Crossref","is-referenced-by-count":1,"title":["The influence of cytotoxic drugs on the immunophenotype of blast cells in paediatric B precursor acute lymphoblastic leukaemia"],"prefix":"10.2478","volume":"58","author":[{"given":"Tomaz","family":"Prelog","sequence":"first","affiliation":[{"name":"Department of Haemato-Oncology, University Children\u2019s Hospital , University Medical Centre Ljubljana , Ljubljana , Slovenia"},{"name":"Faculty of Medicine , University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Bucek","sequence":"additional","affiliation":[{"name":"Department of Cytopathology , Institute of Oncology Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreja","family":"Brozic","sequence":"additional","affiliation":[{"name":"Department of Cytopathology , Institute of Oncology Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Peterlin","sequence":"additional","affiliation":[{"name":"Institute for Biostatistics and Medical Informatics , University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Kavcic","sequence":"additional","affiliation":[{"name":"Department of Haemato-Oncology, University Children\u2019s Hospital , University Medical Centre Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masa","family":"Omerzel","sequence":"additional","affiliation":[{"name":"Department of Experimental Oncology , Institute of Oncology Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bostjan","family":"Markelc","sequence":"additional","affiliation":[{"name":"Department of Experimental Oncology , Institute of Oncology Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Jesenko","sequence":"additional","affiliation":[{"name":"Faculty of Medicine , University of Ljubljana , Ljubljana , Slovenia"},{"name":"Department of Experimental Oncology , Institute of Oncology Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika Kloboves","family":"Prevodnik","sequence":"additional","affiliation":[{"name":"Faculty of Medicine , University of Ljubljana , Ljubljana , Slovenia"},{"name":"Department of Cytopathology , Institute of Oncology Ljubljana , Ljubljana , Slovenia"},{"name":"Institute of Pathology, Faculty of Medicine University of Maribor , Maribor , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"key":"2026071211371474098_j_raon-2024-0006_ref_001","unstructured":"Campbell M, Castillo L, Riccheri C, Janic D, Jazbec J, Kaiserova E, et al. ALL ICBFM 2009. A randomized trial of the I-BFM-SG for the management of childhood non-B acute lymphoblastic leukemia. Final version of therapy protocol from August 14 2009. [Internet]. [cited 2023 Mar 15]. Available at https:\/\/www.bialaczka.org\/wp-content\/uploads\/2016\/10\/ALLIC_BFM_2009.pdf"},{"key":"2026071211371474098_j_raon-2024-0006_ref_002","doi-asserted-by":"crossref","unstructured":"Maury S, Chevret S, Thomas X, Heim D, Leguay T, Huguet F, et al. Rituximab in B-lineage adult acute lymphoblastic leukemia. N Engl J Med 2016; 375: 1044\u201353. doi: 10.1056\/nejmoa1605085","DOI":"10.1056\/NEJMoa1605085"},{"key":"2026071211371474098_j_raon-2024-0006_ref_003","doi-asserted-by":"crossref","unstructured":"Hayden PJ, Roddie C, Bader P, Basak, GW, Bonig H, Bonini C, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol 2022; 33: 259\u201375. doi: 10.1016\/j.annonc.2021.12.003","DOI":"10.1016\/j.annonc.2021.12.003"},{"key":"2026071211371474098_j_raon-2024-0006_ref_004","doi-asserted-by":"crossref","unstructured":"Li Y, Moriyama T, Yoshimura S, Zhao X, Li Z, Yang X, et al. PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia. Sci Adv 2022; 8: eadd6403. doi: 10.1126\/sciadv.add6403","DOI":"10.1126\/sciadv.add6403"},{"key":"2026071211371474098_j_raon-2024-0006_ref_005","doi-asserted-by":"crossref","unstructured":"Yan X, Chen D, Ma X, Wang Y, Guo Y, Wei J, et al. CD58 loss in tumor cells confers functional impairment of CAR T cells. Blood Adv 2022; 6: 5844\u201356. doi: 10.1182\/bloodadvances.2022007891","DOI":"10.1182\/bloodadvances.2022007891"},{"key":"2026071211371474098_j_raon-2024-0006_ref_006","doi-asserted-by":"crossref","unstructured":"Hunger SP, Raetz EA. How I treat relapsed acute lymphoblastic leukemia in the pediatric population. Blood 2020; 136: 1803\u201312. doi: 10.1182\/blood.2019004043","DOI":"10.1182\/blood.2019004043"},{"key":"2026071211371474098_j_raon-2024-0006_ref_007","doi-asserted-by":"crossref","unstructured":"Dworzak MN, Schumich A, Printz D, P\u00f6tschger U, Husak Z, Attarbaschi A, et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood 2008; 112: 3982\u201388. doi: 10.1182\/blood-2008-06-164129","DOI":"10.1182\/blood-2008-06-164129"},{"key":"2026071211371474098_j_raon-2024-0006_ref_008","doi-asserted-by":"crossref","unstructured":"Gaipa G, Basso G, Maglia O, Leoni V, Faini A, Cazzaniga G, et al. Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. Leukemia 2005; 19: 49\u201356. doi: 10.1038\/sj.leu.2403559","DOI":"10.1038\/sj.leu.2403559"},{"key":"2026071211371474098_j_raon-2024-0006_ref_009","doi-asserted-by":"crossref","unstructured":"Gaipa G, Basso G, Aliprandi S, Migliavacca M, Vallinoto C, Maglia O, et al. Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells. Cytometry B Clin Cytom 2008; 74: 150\u20135. doi: 10.1002\/cyto.b.20408","DOI":"10.1002\/cyto.b.20408"},{"key":"2026071211371474098_j_raon-2024-0006_ref_010","doi-asserted-by":"crossref","unstructured":"van der Sluijs-Gelling AJ, van der Velden VHJ, Roeffen ETJM, Veerman AJP, van Wering ER. Immunophenotypic modulation in childhood precursor-BALL can be mimicked in vitro and is related to the induction of cell death. Leukemia 2005; 19: 1845\u20137. doi: 10.1038\/sj.leu.2403911","DOI":"10.1038\/sj.leu.2403911"},{"key":"2026071211371474098_j_raon-2024-0006_ref_011","doi-asserted-by":"crossref","unstructured":"Chen D, Gerasim\u010dik N, Camponeschi A, Tan Y, Wu Q, Brynjolfsson S, et al. CD27 expression and its association with clinical outcome in children and adults with pro-B acute lymphoblastic leukemia. Blood Cancer J 2017; 7: e575. doi: 10.1038\/bcj.2017.55","DOI":"10.1038\/bcj.2017.55"},{"key":"2026071211371474098_j_raon-2024-0006_ref_012","doi-asserted-by":"crossref","unstructured":"Riether C, Sch\u00fcrch CM, B\u00fchrer ED, Hinterbrandner M, Huguenin AL, Hoepner S, et al. CD70\/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. J Exp Med 2017; 214: 359\u201380. doi: 10.1084\/jem.20152008","DOI":"10.1084\/jem.20152008"},{"key":"2026071211371474098_j_raon-2024-0006_ref_013","doi-asserted-by":"crossref","unstructured":"Starzer AM, Berghoff AS. New emerging targets in cancer immunotherapy: CD27 (TNFRSF7). ESMO Open 2020; 4(Suppl 3): e000629. doi: 10.1136\/esmoopen-2019-000629","DOI":"10.1136\/esmoopen-2019-000629"},{"key":"2026071211371474098_j_raon-2024-0006_ref_014","doi-asserted-by":"crossref","unstructured":"Aljurf M, Chaudhri NA, Almhareb F, Walter CU, Nounou R, Khalil S, et al. CD34 expression in adult acute lymphoblastic leukemia (ALL) Is a favorable prognostic factor in patients treated with stem cell transplant in first remission. Blood 2011; 118: 4091. doi: 10.1182\/blood.v118.21.4091.4091","DOI":"10.1182\/blood.V118.21.4091.4091"},{"key":"2026071211371474098_j_raon-2024-0006_ref_015","doi-asserted-by":"crossref","unstructured":"Dakka N, Bellaoui H, Bouzid N, Khattab M, Bakri Y, Benjouad A. CD10 and CD34 expression in childhood acute lymphoblastic leukemia in morocco: clinical relevance and outcome. Pediatr Hematol Oncol 2009; 26: 216\u201331. doi: 10.1080\/07357900902897557","DOI":"10.1080\/07357900902897557"},{"key":"2026071211371474098_j_raon-2024-0006_ref_016","doi-asserted-by":"crossref","unstructured":"Cario G, Rhein P, Mitl\u00f6hner R, Zimmermann M, Bandapalli OR, Romey R, et al. High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica 2014; 99: 103\u201310. doi: 10.3324\/haematol.2013.090225","DOI":"10.3324\/haematol.2013.090225"},{"key":"2026071211371474098_j_raon-2024-0006_ref_017","doi-asserted-by":"crossref","unstructured":"Guillaume N, Penther D, Vaida I, Gruson B, Harrivel V, Claisse JF, et al. CD66c expression in B-cell acute lymphoblastic leukemia: strength and weakness. Int J Lab Hematol 2011; 33: 92\u20136. doi: 10.1111\/j.1751-553X.2010.01254.x","DOI":"10.1111\/j.1751-553X.2010.01254.x"},{"key":"2026071211371474098_j_raon-2024-0006_ref_018","doi-asserted-by":"crossref","unstructured":"Kiyokawa N, Iijima K, Tomita O, Miharu M, Hasegawa D, Kobayashi K, et al. Significance of CD66c expression in childhood acute lymphoblastic leukemia. Leuk Res 2014; 38: 2\u201348. doi: 10.1016\/j.leukres.2013.10.008","DOI":"10.1016\/j.leukres.2013.10.008"},{"key":"2026071211371474098_j_raon-2024-0006_ref_019","unstructured":"Consolini R, Legitimo A, Rondelli R, Guguelmi C, Barisone E, Lippi A, et al. Clinical relevance of CD10 expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP). Haematologica 1998; 83: 967\u201373. PMID: 9864914"},{"key":"2026071211371474098_j_raon-2024-0006_ref_020","doi-asserted-by":"crossref","unstructured":"Mitwasi N, Arndt C, Loureiro LR, Kegler A, Fasslrinner F, Berndt N, et al. Targeting CD10 on B-cell leukemia using the universal CAR T-cell platform (UniCAR). Int J Mol Sci 2022; 23: 4912. doi: 10.3390\/ijms23094920","DOI":"10.3390\/ijms23094920"},{"key":"2026071211371474098_j_raon-2024-0006_ref_021","doi-asserted-by":"crossref","unstructured":"G\u00f6kbuget N, Hoelzer D. Treatment with monoclonal antibodies in acute lymphoblastic leukemia: Current knowledge and future prospects. Ann Hematol 2004; 83: 201\u20135. doi: 10.1007\/s00277-003-0752-8","DOI":"10.1007\/s00277-003-0752-8"},{"key":"2026071211371474098_j_raon-2024-0006_ref_022","doi-asserted-by":"crossref","unstructured":"Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol 2012; 1: 1\u20137. doi: 10.1186\/2162-3619-1-36","DOI":"10.1186\/2162-3619-1-36"},{"key":"2026071211371474098_j_raon-2024-0006_ref_023","doi-asserted-by":"crossref","unstructured":"Brown PA, Ji L, Xu X, Devidas M, Hogan L, Borowitz JB, et al. A randomized phase 3 trial of blinatumomab vs. chemotherapy as post-reinduction therapy in high and intermediate risk (HR\/IR) first relapse of B-acute lymph-oblastic leukemia (B-ALL) in children and adolescents\/young adults (AYAs) demonstrates superior efficacy and tolerability of blinatumomab: a report from children\u2019s oncology group study AALL1331. Blood 2019; 134(Suppl 2): LBA-1. doi: 10.1182\/blood-2019-132435","DOI":"10.1182\/blood-2019-132435"},{"key":"2026071211371474098_j_raon-2024-0006_ref_024","doi-asserted-by":"crossref","unstructured":"Fabrizio VA, Phillips CL, Lane A, Baggott C, Prabhu S, Egeler E, et al. Tisagenlecleucel outcomes in relapsed\/refractory extramedullary ALL: A Pediatric Real World CAR Consortium Report. Blood Adv 2022; 6: 600\u201310. doi: 10.1182\/bloodadvances.2021005564","DOI":"10.1182\/bloodadvances.2021005564"},{"key":"2026071211371474098_j_raon-2024-0006_ref_025","doi-asserted-by":"crossref","unstructured":"Schnitzlein WM, Zuckermann FA. Determination of the specificity of CD45 and CD45R monoclonal antibodies through the use of transfected hamster cells producing individual porcine CD45 isoforms. Vet Immunol Immunopathol 1998; 60: 389\u2013401. doi: 10.1016\/S0165-2427(97)00113-X","DOI":"10.1016\/S0165-2427(97)00113-X"},{"key":"2026071211371474098_j_raon-2024-0006_ref_026","doi-asserted-by":"crossref","unstructured":"Balasubramanian P, Singh J, Verma D, Kumar R, Bakhshi S, Tanwar P, et al. Prognostic significance of CD45 antigen expression in pediatric acute lymphoblastic leukemia. Blood Cells Mol Dis 2021; 89: 102562. doi: 10.1016\/j.bcmd.2021.102562","DOI":"10.1016\/j.bcmd.2021.102562"},{"key":"2026071211371474098_j_raon-2024-0006_ref_027","doi-asserted-by":"crossref","unstructured":"Zhang Y, Liu Q, Yang S, Liao Q. CD58 Immunobiology at a glance. Front Immunol 2021; 12: 1\u201320. doi: 10.3389\/fimmu.2021.705260","DOI":"10.3389\/fimmu.2021.705260"},{"key":"2026071211371474098_j_raon-2024-0006_ref_028","doi-asserted-by":"crossref","unstructured":"Zhang X, Voskens CJ, Sallin M, Maniar A, Montes CL, Zhang Y, et al. CD137 promotes proliferation and survival of human B cells. J Immunol 2010; 184: 787\u201395. doi: 10.4049\/jimmunol.0901619","DOI":"10.4049\/jimmunol.0901619"},{"key":"2026071211371474098_j_raon-2024-0006_ref_029","unstructured":"Pieters R, Schrappe M, Valsecchi MG, Biondi A, de Rossi G, Suppiah R, et al. International collaborative treatment protocol for the infants under one year with acute lymphoblastic or biphenotypic leukemia - INTERFANT 06. 2008; version 11(17 July 2007). Cochrane Central Register of Controlled Trials. Available at: https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-01834165\/full"},{"key":"2026071211371474098_j_raon-2024-0006_ref_030","doi-asserted-by":"crossref","unstructured":"Brozic A, Pohar Marinsek Z, Novakovic S, Kloboves Prevodnik V. Inconclusive flow cytometric surface light chain results; can cytoplasmic light chains, Bcl-2 expression and PCR clonality analysis improve accuracy of cytological diagnoses in B-cell lymphomas? Diagn Pathol 2015; 10: 1\u201310. doi: 10.1186\/s13000-015-0427-5","DOI":"10.1186\/s13000-015-0427-5"},{"key":"2026071211371474098_j_raon-2024-0006_ref_031","unstructured":"Bro\u017ei\u010d A. [Clonality and antigenic properties of reactive and neoplastic lymphocytic proliferations]. [Slovenian]. Doctoral Dissertation; 2016. [Internet]. Available at: https:\/\/repozitorij.uni-lj.si\/IzpisGradiva.php?lang=slv&id=84423"},{"key":"2026071211371474098_j_raon-2024-0006_ref_032","unstructured":"Team RC. A Language and environment for statistical computing. Vienna: R Foundation for Statistical Computin; 2020. [Internet]. [cited 2023 Feb 15]. Available at: cwww.r-project.org\/"},{"key":"2026071211371474098_j_raon-2024-0006_ref_033","doi-asserted-by":"crossref","unstructured":"Bezanson J, Edelman A, Karpinski S, Shah VB. Julia: a fresh approach to numerical computing. SIAM Rev 2017; 59: 65\u201398. doi: 10.1137\/141000671","DOI":"10.1137\/141000671"},{"key":"2026071211371474098_j_raon-2024-0006_ref_034","unstructured":"Pinheiro J, Bates D, DebRoy S, Sarkar D. Team, R.C. Nlme: Linear and Nonlinear Mixed Effects Models. R Package Version Nov 27 2023. [Internet]. [cited 2023 Dec]. Available at: https:\/\/cran.r-project.org\/web\/packages\/nlme\/nlme.pdf"},{"key":"2026071211371474098_j_raon-2024-0006_ref_035","unstructured":"Bates D, Alday P, Kleinschmidt D, Calder\u00f3n JBS, Noack A, Kelman T, et al. JuliaStats\/MixedModels.jl: v2.3.0 (v2.3.0). Zenodo; 2020 [Internet]. [cited 2023 Feb 16]. Available at: https:\/\/doi.org\/10.5281\/ZENODO.3727845"},{"key":"2026071211371474098_j_raon-2024-0006_ref_036","doi-asserted-by":"crossref","unstructured":"Peterlin J, Kej\u017ear N, Blagus R. Correct specification of design matrices in linear mixed effects models: tests with graphical representation. TEST 2023; 32: 184\u2013210. doi: 10.1007\/s11749-022-00830-1","DOI":"10.1007\/s11749-022-00830-1"},{"key":"2026071211371474098_j_raon-2024-0006_ref_037","doi-asserted-by":"crossref","unstructured":"Dworzak MN, Gaipa G, Schumich A, Maglia O, Ratei R, Veltroni M, et al. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-study group. Cytometry B Clin Cytom 2010; 78: 147\u201353. doi: 10.1002\/cyto.b.20516","DOI":"10.1002\/cyto.b.20516"},{"key":"2026071211371474098_j_raon-2024-0006_ref_038","doi-asserted-by":"crossref","unstructured":"Espinoza-Gutarra MR, Agarwal P, Ferrer L, Czader M, Dave U. Relationship between CD45 expression and outcomes in B lymphoblastic leukemia\/lymphoma. Blood 2020; 136(Suppl 1): 24. doi: 10.1182\/blood-2020-142085","DOI":"10.1182\/blood-2020-142085"},{"key":"2026071211371474098_j_raon-2024-0006_ref_039","doi-asserted-by":"crossref","unstructured":"Schwarz H, Valbracht J, Tuckwell J, Von Kempis J, Lotz M. ILA the human 4-1BB homologue, is inducible in lymphoid and other cell lineages. Blood 1995; 85: 1043\u201352. doi: 10.1182\/blood.v85.4.1043.bloodjournal8541043","DOI":"10.1182\/blood.V85.4.1043.bloodjournal8541043"},{"key":"2026071211371474098_j_raon-2024-0006_ref_040","doi-asserted-by":"crossref","unstructured":"Borst J, Hendriks J, Xiao Y. CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol 2005; 17: 275\u201381. doi: 10.1016\/j.coi.2005.04.004","DOI":"10.1016\/j.coi.2005.04.004"},{"key":"2026071211371474098_j_raon-2024-0006_ref_041","doi-asserted-by":"crossref","unstructured":"Agematsu K, Hokibara S, Nagumo H, Komiyama A. CD27: a memory B-cell marker. Immunol Today 2000; 21: 204\u20136. doi: 10.1016\/S0167-5699(00)01605-4","DOI":"10.1016\/S0167-5699(00)01605-4"},{"key":"2026071211371474098_j_raon-2024-0006_ref_042","doi-asserted-by":"crossref","unstructured":"Taraban VY, Rowley TF, Kerr JP, Willoughby JE, Johnson PM, Al-Shamkhani A, et al. CD27 costimulation contributes substantially to the expansion of functional memory CD8+ T cells after peptide immunization. Eur J Immunol 2013; 43: 3314\u201323. doi: 10.1002\/eji.201343579","DOI":"10.1002\/eji.201343579"},{"key":"2026071211371474098_j_raon-2024-0006_ref_043","doi-asserted-by":"crossref","unstructured":"Vitale LA, He LZ, Thomas LJ, Widger J, Weidlick J, Crocker A, et al. Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia. Clin Cancer Res 2012; 18: 3812\u201321. doi: 10.1158\/1078-0432.CCR-11-3308","DOI":"10.1158\/1078-0432.CCR-11-3308"},{"key":"2026071211371474098_j_raon-2024-0006_ref_044","doi-asserted-by":"crossref","unstructured":"Biondi A, Schrappe M, De Lorenzo P, Castor A, Lucchini G, Gandemer V, Pieters R, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol 2012; 13: 936\u201345. doi: 10.1016\/S1470-2045(12)70377-7","DOI":"10.1016\/S1470-2045(12)70377-7"}],"container-title":["Radiology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/raon-2024-0006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:05:30Z","timestamp":1783901130000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/raon-2024-0006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,2,21]]},"published-print":{"date-parts":[[2024,3,1]]}},"alternative-id":["10.2478\/raon-2024-0006"],"URL":"https:\/\/doi.org\/10.2478\/raon-2024-0006","relation":{},"ISSN":["1581-3207"],"issn-type":[{"value":"1581-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,21]]}}}